

Minshan Chen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5322993/publications.pdf>

Version: 2024-02-01

44
papers

2,139
citations

471509
17
h-index

265206
42
g-index

45
all docs

45
docs citations

45
times ranked

2665
citing authors

#	ARTICLE	IF	CITATIONS
1	Global patterns of hepatocellular carcinoma management from diagnosis to death: the <sc>BRIDGE</sc> Study. Liver International, 2015, 35, 2155-2166.	3.9	813
2	Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer, 2020, 9, 682-720.	7.7	427
3	IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation. Future Oncology, 2020, 16, 975-989.	2.4	136
4	Chinese Expert Consensus on Multidisciplinary Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus (2018 Edition). Liver Cancer, 2020, 9, 28-40.	7.7	93
5	Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation. Radiology, 2018, 287, 705-714.	7.3	59
6	Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus: 2016 edition. Oncotarget, 2017, 8, 8867-8876.	1.8	56
7	Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition). Hepatobiliary Surgery and Nutrition, 2022, 11, 227-252.	1.5	55
8	Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma. Radiology, 2019, 292, 237-247.	7.3	53
9	42,573 cases of hepatectomy in China: a multicenter retrospective investigation. Science China Life Sciences, 2018, 61, 660-670.	4.9	51
10	Overexpression of LAMC1 predicts poor prognosis and enhances tumor cell invasion and migration in hepatocellular carcinoma. Journal of Cancer, 2017, 8, 2992-3000.	2.5	40
11	Tumor Location Influences Oncologic Outcomes of Hepatocellular Carcinoma Patients Undergoing Radiofrequency Ablation. Cancers, 2018, 10, 378.	3.7	36
12	Derived neutrophil to lymphocyte ratio predicts prognosis for patients with HBV-associated hepatocellular carcinoma following transarterial chemoembolization. Oncology Letters, 2016, 11, 2987-2994.	1.8	30
13	A monocyte/granulocyte to lymphocyte ratio predicts survival in patients with hepatocellular carcinoma. Scientific Reports, 2015, 5, 15263.	3.3	27
14	Postoperative Adjuvant Transarterial Infusion Chemotherapy with FOLFOX Could Improve Outcomes of Hepatocellular Carcinoma Patients with Microvascular Invasion: A Preliminary Report of a Phase III, Randomized Controlled Clinical Trial. Annals of Surgical Oncology, 2020, 27, 5183-5190.	1.5	25
15	Lack of Response to Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: Abandon or Repeat?. Radiology, 2021, 298, 680-692.	7.3	23
16	Antiviral therapy in the improvement of survival of patients with hepatitis <sc>B</sc> virus-related hepatocellular carcinoma treated with sorafenib. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1032-1039.	2.8	22
17	A novel inflammation-based nomogram system to predict survival of patients with hepatocellular carcinoma. Cancer Medicine, 2018, 7, 5027-5035.	2.8	22
18	Design and rationale of the HCC BRIDGE study in China: a longitudinal, multicenter cohort trial in hepatocellular carcinoma. BMC Gastroenterology, 2011, 11, 53.	2.0	18

#	ARTICLE	IF	CITATIONS
19	Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications. BMC Cancer, 2022, 22, 293.	2.6	18
20	The beneficial effects of intermittent fasting: an update on mechanism, and the role of circadian rhythm and gut microbiota. Hepatobiliary Surgery and Nutrition, 2020, 9, 597-602.	1.5	16
21	Transarterial Chemoembolization Combined with Radiofrequency Ablation in the Treatment of Stage B1 Intermediate Hepatocellular Carcinoma. Journal of Oncology, 2019, 2019, 1-7.	1.3	15
22	Transcatheter arterial chemoembolization (TACE) versus hepatectomy in hepatocellular carcinoma with macrovascular invasion: a meta-analysis of 1683 patients. Journal of Cancer, 2017, 8, 2984-2991.	2.5	13
23	High expression of TACC2 in hepatocellular carcinoma is associated with poor prognosis. Cancer Biomarkers, 2018, 22, 611-619.	1.7	9
24	Transarterial Chemoembolization Combined With Hepatectomy for the Treatment of Intermediate-Stage Hepatocellular Carcinoma. Frontiers in Oncology, 2020, 10, 578763.	2.8	8
25	Targeting SGK1 enhances the efficacy of radiotherapy in locally advanced rectal cancer. Biomedicine and Pharmacotherapy, 2020, 125, 109954.	5.6	7
26	Comparison Between Portal Vein Perfusion Chemotherapy and Neoadjuvant Hepatic Arterial Infusion Chemotherapy for Resectable Intermediate to Advanced Stage Hepatocellular Carcinoma. Annals of Surgical Oncology, 2022, 29, 2016-2029.	1.5	7
27	Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation. Viruses, 2022, 14, 656.	3.3	6
28	Chinese expert recommendations on management of hepatocellular carcinoma during COVID-19 pandemic: a nationwide multicenter survey. Hpb, 2022, 24, 342-352.	0.3	5
29	Antiviral Treatments Eliminate the Adverse Impacts of High Baseline HBV Loads on the Survival of HBV-Related HCC Patients. Journal of Hepatocellular Carcinoma, 2022, Volume 9, 315-325.	3.7	5
30	Single-Port Laparoscopic Hepatectomy for Liver Tumor: Operative Steps (With Video). Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2019, 29, e98-e101.	0.8	3
31	Single versus multiple port laparoscopic left lateral sectionectomy for hepatocellular carcinoma: A retrospective comparative study. International Journal of Surgery, 2020, 77, 15-21.	2.7	3
32	Surveillance Strategy after Complete Ablation of Initial Recurrent Hepatocellular Carcinoma: A Risk-Based Machine Learning Study. Journal of Vascular and Interventional Radiology, 2021, 32, 1548-1557.e2.	0.5	3
33	Sorafenib as an adjuvant therapy for hepatocellular carcinoma with microvascular invasion after radical resection: A prospective multicenter nonrandomized controlled study.. Journal of Clinical Oncology, 2020, 38, e16685-e16685.	1.6	3
34	Three-dimensional bioprinted liver tissue for transplantation: hope or hype?. Hepatobiliary Surgery and Nutrition, 2020, 9, 788-790.	1.5	3
35	Family history of hepatocellular carcinoma is not associated with its patients's prognosis after hepatectomy. World Journal of Surgical Oncology, 2013, 11, 280.	1.9	2
36	Association of Virological Response to Antiviral Therapy With Survival in Intermediate-Stage Hepatitis B Virus-Related Hepatocellular Carcinoma After Chemoembolization. Frontiers in Oncology, 2021, 11, 751777.	2.8	2

#	ARTICLE	IF	CITATIONS
37	Transarterial infusion chemotherapy (TAI) combined with Sintilimab in locally advanced, potentially resectable hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2020, 38, e16593-e16593.	1.6	2
38	Transarterial Infusion Chemotherapy with FOLFOX Could be an Effective and Safe Treatment for Unresectable Intrahepatic Cholangiocarcinoma. Journal of Oncology, 2022, 2022, 1-7.	1.3	2
39	The role of neoadjuvant conventional transarterial chemoembolization with radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma after initial hepatectomy with microvascular invasion. International Journal of Hyperthermia, 2022, 39, 688-696.	2.5	2
40	The mutation of hepatitis B virus and the prognosis of hepatocellular carcinoma after surgery: a pilot study. Cancer Management and Research, 2018, Volume 10, 599-611.	1.9	1
41	Surveillance Strategy for Barcelona Clinic Liver Cancer B Hepatocellular Carcinoma Achieving Complete Response: An Individualized Risk-Based Machine Learning Study. Frontiers in Bioengineering and Biotechnology, 2021, 9, 667641.	4.1	1
42	ASO Visual Abstract: Comparison between Portal Vein Perfusion Chemotherapy and Neoadjuvant Hepatic Arterial Infusion Chemotherapy for Resectable Intermediate/Advanced-Stage Hepatocellular Carcinoma. Annals of Surgical Oncology, 2022, 29, 2032-2033.	1.5	1
43	Clinical practice status of the adjuvant therapy in hepatocellular carcinoma (HCC): A survey of Chinese hepatobiliary surgeons.. Journal of Clinical Oncology, 2022, 40, e16127-e16127.	1.6	1
44	Next generation sequencing reveals the phylogenetic relationship of multi-organ metastatic colon cancer and molecular determinants of metastasis.. Journal of Clinical Oncology, 2020, 38, e13502-e13502.	1.6	0